Clinical trial
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell…
NCT00161590 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00161590 |
|---|---|
| Title | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma |
| Official title | Phase I Study of CHOP Plus Campath (C-CHOP) for the Treatment of T-Cell, Null-Cell, and NK-Cell Lymphomas |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | T-Cell Lymphoma, Lymphoma, Non-Hodgkin's |
| Intervention type | Drug |
| Interventions | CHOP and alemtuzumab |
| Start date | Jul 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Oct 22, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: